141 related articles for article (PubMed ID: 19442054)
1. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1.
Stordal B; Davey R
Curr Cancer Drug Targets; 2009 May; 9(3):354-65. PubMed ID: 19442054
[TBL] [Abstract][Full Text] [Related]
2. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.
Stordal B; Hamon M; McEneaney V; Roche S; Gillet JP; O'Leary JJ; Gottesman M; Clynes M
PLoS One; 2012; 7(7):e40717. PubMed ID: 22792399
[TBL] [Abstract][Full Text] [Related]
3. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1.
Sun KX; Jiao JW; Chen S; Liu BL; Zhao Y
J Ovarian Res; 2015 Dec; 8():80. PubMed ID: 26626440
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
[TBL] [Abstract][Full Text] [Related]
6. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase.
Deng HB; Adikari M; Parekh HK; Simpkins H
Cancer Chemother Pharmacol; 2004 Oct; 54(4):301-7. PubMed ID: 15138708
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.
van Haaften C; van Eendenburg J; Boot A; Corver WE; Haans L; van Wezel T; Trimbos JB
Int J Gynecol Cancer; 2017 Oct; 27(8):1571-1578. PubMed ID: 28604461
[TBL] [Abstract][Full Text] [Related]
9. Expression of BAF57 in ovarian cancer cells and drug sensitivity.
Yamaguchi T; Kurita T; Nishio K; Tsukada J; Hachisuga T; Morimoto Y; Iwai Y; Izumi H
Cancer Sci; 2015 Apr; 106(4):359-66. PubMed ID: 25611552
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
11. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
Chock KL; Allison JM; Shimizu Y; ElShamy WM
Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.
Busschots S; O'Toole S; O'Leary JJ; Stordal B
Exp Cell Res; 2015 Aug; 336(1):1-14. PubMed ID: 25499884
[TBL] [Abstract][Full Text] [Related]
14. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
15. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions.
Bartz SR; Zhang Z; Burchard J; Imakura M; Martin M; Palmieri A; Needham R; Guo J; Gordon M; Chung N; Warrener P; Jackson AL; Carleton M; Oatley M; Locco L; Santini F; Smith T; Kunapuli P; Ferrer M; Strulovici B; Friend SH; Linsley PS
Mol Cell Biol; 2006 Dec; 26(24):9377-86. PubMed ID: 17000754
[TBL] [Abstract][Full Text] [Related]
16. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin.
Kobayashi Y; Seino K; Hosonuma S; Ohara T; Itamochi H; Isonishi S; Kita T; Wada H; Kojo S; Kiguchi K
Gynecol Oncol; 2011 May; 121(2):390-4. PubMed ID: 21272926
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines.
Schöndorf T; Neumann R; Benz C; Becker M; Riffelmann M; Göhring UJ; Sartorius J; von König CH; Breidenbach M; Valter MM; Hoopmann M; Di Nicolantonio F; Kurbacher CM
Recent Results Cancer Res; 2003; 161():111-6. PubMed ID: 12528803
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
Brenes O; Arce F; Gätjens-Boniche O; Díaz C
Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
[TBL] [Abstract][Full Text] [Related]
19. Combination effect of adenovirus-mediated pro-apoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines.
Tsuruta Y; Mandai M; Konishi I; Kuroda H; Kusakari T; Yura Y; Hamid AA; Tamura I; Kariya M; Fujii S
Eur J Cancer; 2001 Mar; 37(4):531-41. PubMed ID: 11267864
[TBL] [Abstract][Full Text] [Related]
20. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
Domagala P; Hybiak J; Rys J; Byrski T; Cybulski C; Lubinski J
Oncotarget; 2016 Oct; 7(42):68662-68673. PubMed ID: 27626685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
